Bold Investment Needed for Cholangiocarcinoma Research Progress

In a significant milestone, the Cholangiocarcinoma Foundation marks its 20th anniversary, highlighting the urgent need for increased investment in research for cholangiocarcinoma, a rare and aggressive bile duct cancer. The foundation’s journey began in October 2005, following the diagnosis of Mark, the brother of the foundation’s co-founder, who was only 38 years old at the time. This diagnosis revealed a stark reality: limited information and treatment options for patients facing rare cancers like cholangiocarcinoma.

During the challenging 15 months between Mark’s diagnosis and his passing, his family transformed into caregivers, advocates, and researchers. Mark’s final request—to leverage their experiences for the benefit of others—led to the establishment of the Cholangiocarcinoma Foundation. The organization now serves as a crucial advocate for patients and families, promoting research, developing resources, and fostering connections that mitigate the isolation often felt in such journeys.

As the foundation enters its third decade, it reflects on the community formed from Mark’s vision and the progress achieved through collaboration. Over the past 20 years, the foundation has witnessed the impact of united efforts in research. In the last three years, seven new treatments for biliary tract cancers have gained FDA approval, a development once deemed improbable.

In 2023, the Cholangiocarcinoma Foundation awarded 11 grants worth $85,000 each to early-career investigators. These grants aim to stimulate innovative research ideas and attract new talent to the field. Global partnerships with researchers, clinicians, and industry leaders are essential in accelerating advancements in diagnostics and treatment options.

“Progress has only been possible because patients have shared their data and experiences, caregivers have voiced their concerns, and researchers have pursued bold ideas,” said a representative from the foundation. This collaborative spirit has proven crucial, especially when funding for rare diseases often falls short.

Despite these advances, the need for continued investment remains critical. Cholangiocarcinoma is still diagnosed at advanced stages, leaving many patients with limited treatment options. The foundation emphasizes that addressing these challenges requires a sustained commitment to research.

February is recognized as Cholangiocarcinoma Awareness Month, a time dedicated to raising awareness about this disease and supporting those affected. The foundation is calling on the community to engage in conversations, share resources, and promote research initiatives.

In its 20th year, the Cholangiocarcinoma Foundation reaffirms its commitment to enhancing research, strengthening global collaborations, and ensuring access to reliable information for families facing this diagnosis. Advocating for patient-centered clinical trials and innovative research funding is paramount.

Mark’s story ignited the foundation’s mission, and the thousands of patients and families served today underscore its importance. The foundation believes that through collaborative investment in research, a brighter future is not only possible but achievable.